Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib

Hiraoka, A; Kumada, T; Tada, T; Hirooka, M; Kariyama, K; Tani, J; Atsukawa, M; Takaguchi, K; Itobayashi, E; Fukunishi, S; Tsuji, K; Ishikawa, T; Tajiri, K; Ochi, H; Yasuda, S; Toyoda, H; Ogawa, C; Nishimura, T; Hatanaka, T; Kakizaki, S; Shimada, N; Kawata, K; Naganuma, A; Kosaka, H; Shibata, H; Aoki, T; Tanaka, T; Ohama, H; Nouso, K; Morishita, A; Tsutsui, A; Nagano, T; Itokawa, N; Okubo, T; Arai, T; Imai, M; Koizumi, Y; Nakamura, S; Joko, K; Iijima, H; Kaibori, M; Hiasa, Y; Kudo, M

Hiraoka, A (通讯作者)，Ehime Prefectural Cent Hosp, Gastroenterol Ctr, 83 Kasuga Cho, Matsuyama, Ehime 7900024, Japan.

CANCER MEDICINE, 2023; 12 (1): 325

Abstract

Background/Aim A comparison of therapeutic efficacy between atezolizumab plus bevacizumab (Atez/Bev) and lenvatinib treatment given as first-line ther......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索